AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc.
1:10-cv-00342
Overview
Parties
Movant
AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)
Represented By
10 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Womble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Defendant
AstraZeneca AB NPE (Individual / Inventor)
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Womble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Mylan Pharmaceuticals Inc. Operating Company
Represented By
6 Attorneys ListedPhillips, Goldman & Spence, P.A.
Phillips, Goldman & Spence, P.A., 1200 North Broom Street
Phillips, Goldman & Spence, P.A.
Phillips, Goldman & Spence, P.A., 1200 North Broom Street
Plaintiff
The Brigham and Women's Hospital, Inc. Operating Company
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Womble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
IPR Pharmaceuticals Inc. Operating Company
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Womble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 6,858,618 Asserted | Asserted Patent | View Official Patent → |
| 🇬🇧 United Kingdom | GB 0028429 | United Kingdom Counterpart | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 2002041895 A1 | PCT World Application | View Official Patent → |
MUSC Foundation for Research Development v. AstraZeneca Pharmaceuticals LP
MUSC Foundation for Research Development v. AstraZeneca Pharmaceuticals LP
Palmetto Pharmaceuticals LLC v. AstraZeneca Pharmaceuticals LP
AstraZeneca UK Limited v. Watson Pharmaceuticals Inc.
AstraZeneca Pharmaceuticals LP v. Sandoz Inc.
AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd.
AstraZeneca Pharmaceuticals LP v. Aurobindo Pharma Limited
AstraZeneca Pharmaceuticals LP v. Glenmark Generics Inc. USA
AstraZeneca Pharmaceuticals LP v. Teva Pharamceuticals USA, Inc.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6858618
Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
|
Filed: 2001-11-16
Issued: 2005-02-22
|
Expired (Term Ended)
+31d PTA
Expires: 2021-12-17
|
|
|
US7030152
Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
|
Filed: 1999-08-31
Issued: 2006-04-18
|
Expired (Term Ended)
Expires: 2019-08-31
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
26
Dispositive
23
Granted
2
Denied
0
Pending / Review
19
Motions by Category
Key Dispositive Motions & Rulings